Biochimica et biophysica acta. Reviews on cancer最新文献_第7页

The role of fatty acid oxidation in the tumor microenvironment: Implications for cancer progression and therapeutic strategies 脂肪酸氧化在肿瘤微环境中的作用：对癌症进展和治疗策略的影响。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-10 DOI: 10.1016/j.bbcan.2025.189474

Nasot Rashed , Wenbin Liu , Xiangjian Luo

引用次数: 0

Beyond repair: Expanding roles of BRCA1 in RNA processing and cancer 超越修复：BRCA1在RNA加工和癌症中的扩展作用。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-11-19 DOI: 10.1016/j.bbcan.2025.189499

Mahsa Rastegar Moghaddam Poorbagher, Manuela Santarosa

{"title":"Beyond repair: Expanding roles of BRCA1 in RNA processing and cancer","authors":"Mahsa Rastegar Moghaddam Poorbagher, Manuela Santarosa","doi":"10.1016/j.bbcan.2025.189499","DOIUrl":"10.1016/j.bbcan.2025.189499","url":null,"abstract":"<div><div>BRCA1 is widely recognized as a guardian of the genome due to its established roles in DNA damage repair and cell cycle regulation. Nevertheless, these functions alone do not fully account for the tissue-specific defects and tumor phenotypes associated with pathogenic BRCA1 variants.</div><div>Accumulating evidence indicates that BRCA1 is also essential for RNA processing. In addition to modulating the activity of RNA polymerases, shaping chromatin architecture, and interacting with key transcription factors, BRCA1 influences splicing-factor function and helps prevent and resolve R-loop accumulation, thereby regulating both transcription and genomic integrity.</div><div>In response to DNA damage, BRCA1 participates in a complex containing components of the mRNA splicing machinery, thus altering the splicing pattern of several DNA damage response (DDR) genes. Moreover, BRCA1 orchestrates the transcription of molecules specific to epithelial and luminal breast cells, such as hormone receptors and growth factors, and factors involved in immune and inflammatory pathways.</div><div>This review discusses and organizes the growing body of evidence demonstrating how BRCA1 integrates transcriptional control and RNA processing and, in doing so, preserves a normal epithelial phenotype.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189499"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Keratinocyte organelle reprogramming as a key player in melanocyte biology in health and disease 角化细胞细胞器重编程在健康和疾病中的黑素细胞生物学中起关键作用。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-11-11 DOI: 10.1016/j.bbcan.2025.189495

Sophia N. Baptista , Alessandra V.S. Faria , Carmen V. Ferreira-Halder

{"title":"Keratinocyte organelle reprogramming as a key player in melanocyte biology in health and disease","authors":"Sophia N. Baptista , Alessandra V.S. Faria , Carmen V. Ferreira-Halder","doi":"10.1016/j.bbcan.2025.189495","DOIUrl":"10.1016/j.bbcan.2025.189495","url":null,"abstract":"<div><div>Melanoma, an aggressive skin cancer, poses significant global health challenges due to its increasing incidence and high metastatic potential. While traditionally focused on genetic mutations, recent research highlights the critical role of cellular organelle dysfunction and intricate inter-organelle communication in both keratinocytes and melanocytes during melanoma pathogenesis. This systematic review explores how alterations within key organelles, including mitochondria, endoplasmic reticulum (ER), Golgi apparatus, lysosomes, peroxisomes, and lamellar bodies. reprogram cellular behavior and contribute to disease progression. We detail how mitochondrial dysfunction and elevated reactive oxygen species (ROS) levels in keratinocytes can prime the microenvironment for melanocyte transformation. Lysosomes and peroxisomes, vital for degradation, lipid metabolism, and redox balance, when compromised, impair cellular differentiation and oxidative stress management, fostering a pro-tumorigenic state. The ER and ribosomes, crucial for protein synthesis and quality control, are frequently impacted by environmental stressors like UV radiation, leading to adaptive or detrimental cellular responses. Furthermore, the proper function of lamellar bodies, essential for skin barrier integrity, is intrinsically linked to Golgi and lysosomal health, with disruptions influencing melanoma dissemination. Understanding the complex interplay and dysregulation of these organelles offers a multifaceted perspective on melanoma, moving beyond isolated cellular events to reveal systemic imbalances. This review underscores the potential for developing novel strategies that target specific organelle pathways, aiming to restore cellular homeostasis and effectively combat tumor progression.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189495"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing 推进肿瘤药物开发：创新方法提高成功率，同时减少动物试验。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI: 10.1016/j.bbcan.2025.189467

Hans Hendriks

{"title":"Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing","authors":"Hans Hendriks","doi":"10.1016/j.bbcan.2025.189467","DOIUrl":"10.1016/j.bbcan.2025.189467","url":null,"abstract":"<div><div>Drug development remains a high-risk endeavour, particularly in oncology, where failure rates exceed 90 %. This review examines emerging tools and strategies designed to enhance preclinical success rates, aligning with the 3Rs principle: Reduction, Refinement, and Replacement of animal testing.</div><div>Traditional 2D in vitro screening remains fundamental in early anticancer drug development due to its cost-effectiveness and reproducibility. However, 3D in vitro culture systems, including patient-derived organoids, better recapitulate tumour structure, providing more accurate predictions of clinical response. Additionally, Organ-on-a-chip platforms further enhance physiological relevance and complement conventional animal toxicology models. Despite their promise, these technologies face challenges in standardisation, validation, and regulatory acceptance.</div><div>Artificial intelligence is also emerging as a transformative tool in oncology drug discovery and development. However, its widespread adoption is currently constrained by limited access to high-quality datasets, concerns around data security, privacy, and underdeveloped computational infrastructure.</div><div>For in vivo studies, patient-derived xenograft (PDX) models remain the gold standard, offering robust and translationally relevant platforms for efficacy testing. Hybrid models, such as PDX-derived organoids and PDX-derived cell cultures, provide complementary systems that integrate in vitro and in vivo insights.</div><div>While these innovations offer long-term potential to reduce animal use, more innovative experimental designs and methods, such as the Single Mouse Trial and the Hollow Fibre Assay, may reduce animal numbers in the short term without compromising data quality.</div><div>Together, these advances contribute to a more ethical, efficient, and predictive framework for the development of preclinical anticancer drugs.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189467"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics 革命性的膀胱癌研究：利用3D类器官技术解码肿瘤异质性并推动个性化治疗。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1016/j.bbcan.2025.189454

Helin Kang , Xi Liu , Dan Ge , Yu Zeng

{"title":"Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics","authors":"Helin Kang , Xi Liu , Dan Ge , Yu Zeng","doi":"10.1016/j.bbcan.2025.189454","DOIUrl":"10.1016/j.bbcan.2025.189454","url":null,"abstract":"<div><div>Bladder cancer (BC), characterized by remarkable tumor heterogeneity, remains a challenging malignancy with limited therapeutic options. Emerging three-dimensional (3D) organoid models are transforming our understanding of BC biology by closely mimicking the complex tumor microenvironment (TME) and cellular interactions, far surpassing traditional two-dimensional (2D) cell culture systems. This review underscores the innovative advances in bladder cancer organoid technology, emphasizing their unique strengths in capturing intratumoral heterogeneity, enhancing drug sensitivity assessments, and facilitating personalized treatment approaches. We discuss diverse organoid systems, including spheroids, assembloids, and patient-derived organoid xenografts (PDOX), highlighting their exceptional ability to replicate individual patient tumor profiles. Furthermore, we explore integrated organoid-on-chip cultivation techniques incorporating 3D bioprinting and microfluidics, which notably improve precision, reproducibility, and scalability in organoid-based drug screening platforms. We advocate for optimized organoid cultivation protocols and synergistic integration with high-throughput analytical technologies, aiming ultimately to accelerate regimen breakthroughs in personalized medicine for bladder cancer patients.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189454"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies STAT3轴在癌症和癌症干细胞：从肿瘤发生到靶向治疗。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-09-29 DOI: 10.1016/j.bbcan.2025.189461

Deepika Godugu, Rameswari Chilamakuri, Saurabh Agarwal

{"title":"STAT3 axis in cancer and cancer stem cells: From oncogenesis to targeted therapies","authors":"Deepika Godugu, Rameswari Chilamakuri, Saurabh Agarwal","doi":"10.1016/j.bbcan.2025.189461","DOIUrl":"10.1016/j.bbcan.2025.189461","url":null,"abstract":"<div><div>The signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that is essential in regulating cellular homeostasis. Aberrant and persistent activation of STAT3 triggers the oncogenic progression of multiple cancers. STAT3 can be activated by both canonical and non-canonical pathways, leading to its nuclear translocation and regulation of the transcription of multiple target genes to promote tumor cell proliferation, drug resistance, differentiation, inflammation, immune evasion, and angiogenesis. Persistent activation of STAT3 correlates with the poor prognosis of cancer patients. Notably, STAT3 plays a crucial role in the maintenance of cancer stem cells (CSCs), contributing to disease relapse, metastasis, and poor clinical outcomes. Given its multifaceted role in tumor biology, STAT3 is an attractive target for therapeutic intervention. Various small molecules, peptides, and natural compounds targeting STAT3 are currently under different stages of preclinical and clinical evaluation. Despite promising advances, challenges such as drug resistance, selectivity, and toxicity remain obstacles in the development of effective STAT3-targeted therapies. This review provides a comprehensive overview of STAT3 structure, activation mechanisms, and its functional role in tumor biology and CSC maintenance. We also highlight current progress in STAT3-targeted therapeutic strategies, including agents in clinical trials, and discuss the future potential of STAT3 inhibition in precision oncology.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189461"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer 重新审视CHK1和WEE1激酶作为癌症治疗靶点的作用

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-22 DOI: 10.1016/j.bbcan.2025.189482

Nehal Arvind Kumar, P. Manasa, Jaikanth Chandrasekaran

{"title":"Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer","authors":"Nehal Arvind Kumar, P. Manasa, Jaikanth Chandrasekaran","doi":"10.1016/j.bbcan.2025.189482","DOIUrl":"10.1016/j.bbcan.2025.189482","url":null,"abstract":"<div><div>Uncontrolled cell division is a defining characteristic of cancer, driven by genomic instability. This instability disrupts the DNA damage response network, exacerbates replication stress, and impairs cell cycle checkpoints. Although conventional DNA-damaging therapies like chemotherapy and radiotherapy exploit this vulnerability, they often cause substantial damage to healthy tissues, leading to adverse effects that may inadvertently promote tumour resilience. Targeted DDR inhibition, exemplified by Poly [ADP-ribose] polymerase inhibitors, has achieved major clinical success, functioning through a synthetic lethality approach in tumours with a defective homologous recombination repair pathway. Extending this strategy to the ATR-CHK1-WEE1 axis, a central responder to replication stress and regulator of intra-S and G2/M checkpoints, offers a promising therapeutic window, particularly in cancers with G1/S checkpoint defects. However, realising this potential requires a deeper understanding of tumour-specific DNA damage response defects, identification of robust biomarkers, and improved patient stratification needs. Currently, the clinical development of CHK1 and WEE1 inhibitors demonstrates their potential, especially in combination with standard-of-care therapies, where they capitalise on elevated replication stress to induce selective tumour cell death. This review outlines recent advances, challenges, and future directions in targeting CHK1 and WEE1 kinases, highlighting their potential to advance precision oncology in the future.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189482"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145358994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The mitochondrial nexus: Targeting metabolic vulnerabilities, oxidative stress, and immunomodulation to induce cancer cell death 线粒体联系：针对代谢脆弱性、氧化应激和免疫调节诱导癌细胞死亡。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-31 DOI: 10.1016/j.bbcan.2025.189491

Woo Hyun Park

{"title":"The mitochondrial nexus: Targeting metabolic vulnerabilities, oxidative stress, and immunomodulation to induce cancer cell death","authors":"Woo Hyun Park","doi":"10.1016/j.bbcan.2025.189491","DOIUrl":"10.1016/j.bbcan.2025.189491","url":null,"abstract":"<div><div>Mitochondria, far from being mere cellular powerhouses, act as central command hubs dictating cell fate by integrating metabolic cues with life-or-death decisions. In cancer, these organelles undergo profound functional and structural reprogramming to support relentless proliferation, survival, and adaptation to stress. This metabolic plasticity, however, creates unique vulnerabilities exploitable for therapeutic gain. This comprehensive review synthesizes recent insights into the multifaceted roles of mitochondria in cancer, focusing on how inhibiting their core functions can trigger diverse cell death pathways and modulate the tumor microenvironment. This paper delves into the central role of mitochondria in orchestrating various forms of regulated cell death (RCD), including apoptosis, ferroptosis, necroptosis, and the newly defined cuproptosis. A primary focus is placed on the dual nature of mitochondrial reactive oxygen species (ROS), which can promote tumorigenesis but can also be pharmacologically elevated to catastrophic levels, triggering oxidative stress-induced demise. This review systematically categorizes and discusses a burgeoning pharmacopeia of mitochondrial inhibitors—targeting the electron transport chain (ETC), metabolic enzymes like glutaminase, protein homeostasis, and ion channels—and analyzes their mechanisms of action, preclinical evidence, and clinical translation status. Furthermore, this paper examines how these agents can overcome chemoresistance and synergize with existing treatments, including the exciting interface with immunotherapy, where mitochondrial fitness is paramount for robust anti-tumor T-cell responses and the induction of immunogenic cell death (ICD). By dissecting the complex interplay between mitochondrial inhibition, metabolic disruption, oxidative stress, and cell death, this review highlights the immense promise of mitochondria-targeted therapies and charts the course for future innovations in oncology.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189491"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer 线粒体DNA异质性的检测方法及其在癌症单细胞中的潜在应用。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-10 DOI: 10.1016/j.bbcan.2025.189472

Tianguang Cheng , Min Pan , Yi Qiao , Jing Tu

{"title":"Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer","authors":"Tianguang Cheng , Min Pan , Yi Qiao , Jing Tu","doi":"10.1016/j.bbcan.2025.189472","DOIUrl":"10.1016/j.bbcan.2025.189472","url":null,"abstract":"<div><div>Mitochondrial DNA (mtDNA) is crucial for cellular metabolism, oxidative stress responses, and genomic stability, with mutations linked to cancer progression and therapeutic resistance. Mitochondrial heteroplasmy, the coexistence of wild-type and mutant mtDNA within a cell or across populations, plays a key role in mitochondrial dysfunction, tumor heterogeneity, and disease pathogenesis. Advances in single-cell technologies like quantitative PCR (qPCR), digital droplet PCR (ddPCR), next-generation sequencing (NGS), and long-read sequencing (TGS) have enabled precise mapping of heteroplasmic variants, providing insights into their role in cancer. This review evaluates current detection methods, discussing their strengths, limitations, and relevance to cancer research. We also explore the biological implications of heteroplasmy in cellular dynamics, nuclear mitochondrial DNA segments (NUMTs), and cancer pathogenesis, highlighting emerging technologies and future directions for studying mtDNA mutations at single-cell resolution in cancer. Ultimately, this review provides a critical synthesis of how single-cell mtDNA heteroplasmy analysis is reshaping our understanding of tumorigenesis and identifies key methodological and challenges that must be addressed to realize its full potential in precision oncology.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189472"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145282154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

E-cadherin: A potential biomarker in cancer and a therapeutic target e -钙粘蛋白：一种潜在的癌症生物标志物和治疗靶点。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-09-26 DOI: 10.1016/j.bbcan.2025.189466

Puja Kumari , Sagarika Dash , Dibyendu Samanta

{"title":"E-cadherin: A potential biomarker in cancer and a therapeutic target","authors":"Puja Kumari , Sagarika Dash , Dibyendu Samanta","doi":"10.1016/j.bbcan.2025.189466","DOIUrl":"10.1016/j.bbcan.2025.189466","url":null,"abstract":"<div><div>Tumorigenesis is a complex, multifaceted process that deregulates normal cellular functions, including cell growth, proliferation, and apoptosis. The primary factors driving tumorigenesis include the activation of oncogenes, inhibition of tumor suppressor genes, and the disruption of cell-cell contact. E-cadherin, a critical component of adherens junctions, plays an integral role in cell adhesion, maintaining tissue integrity, and contributing to developmental processes. E-cadherin facilitates the regulation of proliferation through contact inhibition under physiological conditions, acting as a tumor suppressor, and the alterations in E-cadherin expression are a major driving force in the development of various cancers. However, ongoing research has revealed the significance of E-cadherin in cancer progression, emphasizing its functional duality in tumorigenesis. This review summarizes E-cadherin's diverse and complex functions in various cancers, the underlying molecular mechanisms, and its role as a potential cancer biomarker across different cancer types. Further, we highlight numerous therapeutic strategies designed to target E-cadherin expression to treat various cancers.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189466"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0